Experienced and Highly Focused Management Team

The XORTX team of multi-disciplinary industry professionals is capable of drug development from discovery to marketing approval. Over 60 years of manufacturing, clinical and regulatory drug development experience.

Concept Validating Clinical Trials

Recent human studies have defined a role for chronically increased serum uric acid (SUA) in a disease axis that includes rare-”orphan” diseases, such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, blood pressure, kidney injury, diabetes, and diabetic nephropathy. Stll more recent human studies have shown that decreasing and maintaining lower uric acid levels using..More

Cornerstone Intellectual Property

XORTX Patents and patent applications claim the use of and composition of uric acid lowering agents for the treatment of hypertension, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy and other diseases.

Latest News

XORTX Announces Submission of Orphan Drug Designation Application

Phase II Clinical Study in ADPKD Planned CALGARY, Alberta, Sept. 10, 2018 (GLOBE NEWSWIRE) —  XORTX Therapeutics Inc. (“XORTX” or the...

QBIE™ Spotlight: XORTX Therapeutics Inc. (OTCQB: XRTXF)

QBie™ Spotlight joins Dr. Allen Davidoff, CEO, of XORTX Therapeutics Inc. (OTCQB: XRTXF), to discuss one of the OTCQB’s newest additions....

XORTX Submits FDA pre-IND Meeting Documents

● Advancing to a Phase II Clinical Study in Polycystic Kidney Disease ● CALGARY, Alberta, Aug. 13, 2018 (GLOBE NEWSWIRE) —...